dr. reddy's labs glp-1 receptor agonist weight management diabetes treatments cardinal health GLP-1 Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon New Developments in Pharmacological Treatment
Description
Johansen NJ, Dejgaard TF, Lund A, Schluntz C, Frandsen CS, Forman JL, et al
This 72-week study compared the efficacy and safety of subcutaneous semaglutide 7.2 mg against semaglutide 2.4 mg and a placebo, all administered weekly, in 1,407 adults with obesity who also participated in lifestyle interventions
Study selection We developed eligibility criteria for inclusion in the literature based on the PICOS principles
In terms of eating and dietary changes, 47% of GLP-1 users in PwCs survey reported eating smaller portions, and 56% said they now make healthier food choices
